X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells $34,412.85 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan sold 76,473 shares of the business’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now owns 1,087,386 shares in the company, valued at $489,323.70. The trade was a 6.57 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

X4 Pharmaceuticals Trading Up 52.6 %

Shares of X4 Pharmaceuticals stock opened at $0.74 on Thursday. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals, Inc. has a twelve month low of $0.26 and a twelve month high of $1.60. The firm has a market capitalization of $125.39 million, a PE ratio of -8.17 and a beta of 0.14. The firm’s 50-day moving average price is $0.55 and its 200 day moving average price is $0.61.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Stifel Nicolaus dropped their price target on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $1.50 price target on shares of X4 Pharmaceuticals in a report on Tuesday, January 14th.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Rhumbline Advisers raised its holdings in shares of X4 Pharmaceuticals by 14.6% during the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares during the period. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals in the 3rd quarter valued at about $30,000. XTX Topco Ltd increased its holdings in shares of X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after buying an additional 46,397 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals during the 3rd quarter valued at approximately $37,000. Finally, Point72 Asset Management L.P. lifted its holdings in X4 Pharmaceuticals by 15.1% in the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock valued at $418,000 after acquiring an additional 81,968 shares during the last quarter. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.